Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS‐13 activity and autoantibodies

Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS‐13 activity and autoantibodies

Abstract Recently, treatment of immune‐mediated thrombotic thrombocytopenic purpura (ITTP) has changed with the advent of caplacizumab in clinical practice. The International Working Group (IWG) has recently integrated the ADAMTS‐13 activity/autoantibody monitoring in consensus outcome definitions....

Full description

Bibliographic Details
Main Authors: Francesca Palandri, Christian Di Pietro, Francesca Ricci, Pier Luigi Tazzari, Vanda Randi, Daniela Bartoletti, Michele Cavo, Nicola Vianelli, Giuseppe Auteri
Format: Article
Language:English
Published: Elsevier 2021-12-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
ADAMTS‐13
caplacizumab
COVID‐19
rituximab
thrombotic thrombocytopenic purpura
TTP
Online Access:https://doi.org/10.1002/rth2.12606

Internet

https://doi.org/10.1002/rth2.12606

Similar Items